Key result
HFpEF remains challenging to diagnose with limited survival-enhancing therapies despite comorbidity management.
Why the study?
Despite advances, HFpEF remains a diagnostic challenge, and therapies aimed at enhancing survival and improving quality of life are limited.
Key points are not available for this paper at this time.
Design
Review
HFpEF diagnosis and survival gains remain limited despite comorbidity focus; leaves open need for targeted therapies in prospective trials.
Heart failure with preserved ejection fraction (HFpEF) includes almost half of heart failure cases typified by a specific clinical syndrome. Despite diagnostic and management advances, HFpEF still presents a diagnostic challenge and a paucity of therapies specifically aimed at enhancing survival and improving quality of life is still lacking. This review elucidates the diagnostic complexity of HFpEF, highlighting the use of both subjective and objective criteria within algorithmic frameworks. It also examines the significant impact of comorbidities on the progression of HFpEF. Additionally, we explore the latest evidence on targeting these comorbidities therapeutically, although the benefits to mortality are still limited.
No takes yet. Share an insight, caveat, or question.
Shahid et al. (2024) studied this question. Heart failure with preserved ejection fraction remains challenging to diagnose, with limited therapies that enhance survival despite addressing comorbidities.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: